肺癌的分子靶向治疗进展现状

近年来,分子靶向治疗在肺癌治疗领域取得了显著进展.与传统疗法相比,其优越性表现在:特异性强、亲和性高,在杀死肿瘤细胞的同时不杀死或极少杀伤正常细胞,不良反应轻,耐受性好.现阶段临床上研究较多的有针对表皮生长因子受体的药物吉非替尼、厄罗替尼、西妥昔单抗、曲妥珠单抗等,以及抗肿瘤血管生成药物贝伐单抗等.这些药物的临床实践证明其能给患者带来生存效益.随着研究的进展,新型药物日益增多.靶向治疗联合放化疗和靶向药物之间的联合等新型疗法亦不断涌现.总之,肺癌分子靶向治疗药物应用前景广阔,在传统疗法的疗效达到平台时,为肺癌的治疗开辟了新的方向.

Status of molecular targeted therapies in lung cancer

In recent years, the molecular targeted therapy of lung cancer has made significant progress. Compared with traditional therapy, its superiority displays in strong specificity, high affinity, not or seldom killing normal cell while killing the tumor cell,light toxicity,good tolerability. At this stage,targeted therapies of clinical research are mostly gefitinib, erlotinib, cetuximab, trastuzumab for epidermal growth factor receptor and anti-angiogenesis drug bevacizumab. The clinical trials of the drugs have proved that they can bring survival benefit for the patients. With the progress of the study, new drugs turn up increasingly. New therapies, such as targeted therapy combined chemotherapy and radiotherapy, targeted therapy joint and so on,are also emerging. In short, the use of molecular targeted therapy drugs on lung cancer has a wide perspective. It opens a new direction for the treatment of lung cancer when the efficacy of the traditional therapies reaches the platform.